Objective To explore the potential mechanism of Shengqing Capsule（升清胶囊

SC） in treating cholelithiasis. Methods Human L-02 hepatocytes were divided into normal group

model group and SC high

medium and low dose groups and ursodeoxycholic acid（UDCA） high

medium and low dose groups. The cholesterol deposition model was induced by liver X receptor（LXR） agonists in all groups except the normal group. Each treatment group was given 2ml serum containing 10% corresponding medicine for each hole

while the normal group and the model group were given 2ml blank serum for each hole. After 24 hours

volumes of total cholesterol（TC） in supernatant and cells in each group were observed

so were the mRNA and protein expressions of LXR-α

FXR

ABCA1

ABCG5 and ABCG8. Results In the model group

TC volume in both supernatant and cells

and the mRNA and protein expressions of LXR-α

FXR

ABCA1

ABCG5 and ABCG8 were all significantly higher than those in the normal group（P < 0. 01）. While in each treatment group

they all decreased in varying degrees; in addition

SC and UDCA showed dose-dependence in decreasing LXR-α and ABCA1 proteins

with the best effect in high dose groups（P < 0. 05 or P < 0. 01）. In downregulating LXR-α mRNA expression

the high dose SC group behaved significantly better than the high dose UDCA group（P < 0. 01）. Conclusion By downregulating the mRNA and protein expressions of LXR-α and FXR

as well as their direct target gene ABCA1

ABCg4 and ABCG8

SC may ameliorate the cholesterol deposition in hepatocytes to inhibit the formation and development of calculi.